Skip to main content
Equibles
NEOG logo

NEOG · Neogen Corp

Track NEOG — free

Use NEOG with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$11.66 -0.08 (-0.68%) At close · Aug 28
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$2.56B
Shares
218.06M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$11.66 Open$11.74 Day$11.43–11.79 52W close$5.27–12.15 Avg vol 30d2.0M Short int9.9M · 4.6% float · 4.2d Short vol61% Last earningsJul 30, 2026 DataJun 2021–Aug 2026 Filing10-K · Jul 30

Raw chart and full-history price indicators begin at the captured split on Jun 7, 2021; bars on opposite sides are not compared.

Up next

Next earnings call
Oct 29, 2026 Est · unconfirmed · in 9 wks
FQ1-27 quarter ends
~Aug 31, 2026 Est
Latest filing: 10-K
filed Jul 30, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Equibles Rating

      blended score · not investment advice
      Overall
      Buy
      SellHoldBuy
      Technical Buy Momentum Strong Sentiment Neutral Fundamentals Strong Quant / Vol High
      Market backdrop VIX 14.4 · calm Equity put/call 0.62
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +26%
      above
      Price vs 50-day avg +11%
      above
      RSI (14) 57
      neutral
      MACD trend Negative
      52-week position 93%
      near high
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Strong
      1-month return −3%
      trailing
      6-month return +20%
      trailing
      YTD return +67%
      this year
      Relative strength +7%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $10 › 200d $9 — 50d above 200d
      Institutional flow Accumulating
      +3% holders QoQ · +53 funds added
      Insider flow Accumulating
      Net +$4.4K over 90 days · 0% sells
      Short interest Rising
      4.56% of float · ▲ +5.3% MoM · 4.2 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      319 holders — mid 3-yr range
      Squeeze score 64
      elevated · 0–100
      Fundamentals
      Strong
      Revenue growth −3%
      Y/Y
      Gross margin 47%
      contracting
      EPS growth +99%
      Y/Y
      Free cash flow $81.7M
      Quant / Vol
      risk profile
      High
      Volatility 61%
      annualized · 1-yr
      Max drawdown −28%
      past year
      ATR 3.8%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Beat or met 1 of last 3
      Latest guidance · from the Earnings Call filed May 31, 2026
      fiscal year 27
      Total fiscal year 27 revenue Initiated $880M – $885M
      prior FY $870.4M midpoint +1.4% Y/Y
      Adjusted EBITDA Non-GAAP Initiated $180M – $182M
      Adjusted EBITDA Initiated $180M – $182M
      Adjusted EBITDA margin Initiated 20.5%
      Transformation initiatives Initiated $25M
      first quarter 27
      First quarter 27 revenue Initiated $207M – $209M
      prior qtr $211.2M midpoint −1.5% QoQ
      Adjusted EBITDA Non-GAAP Initiated $37M
      Adjusted EBITDA Initiated $37M
      Prior guidance period ended · from the 8-K filed Jan 8, 2026
      Revenue · fiscal year 2026 $845M – $855M
      Adjusted EBITDA · fiscal year 2026 $175M
      Capital expenditures · fiscal year 2026 $50M
      Guided vs delivered · last 3 settled
      Revenue fiscal year 2026
      guided $845M – $855M
      $870.4M Beat +2.4%
      Revenue full-year
      guided $895M
      $894.7M Miss −0.0%
      Full year revenues full year
      guided $935M – $955M
      $924.2M Miss −2.2%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      1 · 3 · 3
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +26% Bullish
      Price vs 50-day avg
      +11% Bullish
      RSI (14)
      57 Neutral
      MACD trend
      Negative Bearish
      52-week position
      93% Bullish
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bullish · 2 of 6
      Trend (MA cross) No cross
      50d $10 › 200d $9 — 50d above 200d
      Institutional flow Accumulating
      +3% holders QoQ · +53 funds added
      Insider flow Accumulating
      Net +$4.4K over 90 days · 0% sells
      Short interest Rising
      4.56% of float · ▲ +5.3% MoM · 4.2 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      319 holders — mid 3-yr range
      Price context
      position in its 52-week range
      Range low $5 Now $12 · 93% Range high $12
      vs 200-day avg +26% vs 50-day avg +11%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      GAAP → non-GAAP reconciliation
      GAAP Net Loss -7.9M
      -1.1M Income tax benefit
      +116.3M Depreciation and amortization
      +57.6M Interest expense, net
      +13.4M Share-based compensation
      +2.6M FX transaction loss (gain) on loan and other revaluation
      +10.6M Transaction costs
      +1.5M 3M integration costs
      +12.4M Sample collection transition and ramp up costs
      +12M Petrifilm duplicate manufacturing costs
      +22.3M Transformation initiatives and related costs
      +7M Restructuring
      +0M Goodwill impairment
      +0.9M Contingent consideration adjustments
      -76.4M Gain on sale of business
      +2.4M Discontinued product line
      +4.2M Other
      = Adjusted EBITDA 177.8M
      GAAP → non-GAAP reconciliation
      GAAP Gross Profit $408.5M
      +$0.7M Transaction costs
      +$1.5M 3M integration costs
      +$12.4M Sample collection transition and ramp up costs
      +$11.9M Petrifilm duplicate manufacturing costs
      -$0.1M Restructuring
      +$2.4M Discontinued Product line
      +$0.5M Other
      = Adjusted Gross Profit $437.8M
      GAAP → non-GAAP reconciliation
      GAAP Net Loss -$7.9M
      +$89.1M Amortization of acquisition-related intangibles
      +$13.4M Share-based compensation
      +$2.6M FX transaction loss (gain) on loan and other revaluation
      +$10.6M Transaction costs
      +$1.5M 3M integration costs
      +$12.4M Sample collection transition and ramp up costs
      +$12M Petrifilm duplicate manufacturing costs
      +$22.3M Transformation initiatives and related costs
      +$7M Restructuring
      +$0M Goodwill impairment
      +$0.9M Contingent consideration adjustments
      -$76.4M Gain on sale of business
      +$2.4M Discontinued product line
      +$4.2M Other
      -$23.9M Estimated tax effect of above adjustments
      = Adjusted Net Income $70.2M
      Adjusted Operating Expenses non-GAAP $283.9M Twelve months ended May 31, 2026 —
      GAAP → non-GAAP reconciliation
      GAAP Operating Income (Loss) -$21.6M
      +$89.1M Amortization of acquisition-related intangibles
      +$13.4M Share-based compensation
      +$10.1M Transaction costs
      +$1.5M 3M Integration costs
      +$12.4M Sample collection transition and ramp up costs
      +$12M Petrifilm duplicate manufacturing costs
      +$22.3M Transformation initiatives and related costs
      +$7M Restructuring
      +$0M Goodwill impairment
      +$2.4M Discontinued Product line
      +$5.3M Other
      = Adjusted Operating Income $153.9M
      Animal Safety Core Revenue Growth non-GAAP 0.5% Q4 FY26 —
      Core Growth non-GAAP 1.9% Full fiscal year 2026 —
      Food Safety Core Revenue Growth non-GAAP 3.1% FY26 —
      Free Cash Flow non-GAAP $26.2M Q4 FY2026 —
      GAAP → non-GAAP reconciliation
      GAAP Net cash provided by operating activities $30.2M
      -$4M Purchase of PPE
      = Free cash flow $26.2M
      Net debt non-GAAP $608.2M As of May 31, 2026 —
      Adjusted EBITDA margin (% of sales) non-GAAP 19.4% Six months ended November 30, 2025 —
      Committed borrowing capacity 201.5M As of November 30, 2025 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Medical Devices — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      NEOG
      Neogen Corp
      this stock
      		$2.56B +66.8% -2.7% — 4.6%
      ABT
      Abbott Laboratories
      		 $195.90B -10.2% +5.7% 31.5 1.2%
      SYK
      Stryker Corp
      		 $127.12B -5.9% +11.2% 34.3 1.8%
      MDT
      Medtronic plc
      		 $116.78B -5.0% +8.4% 24.5 1.1%
      BSX
      Boston Scientific Corp
      		 $67.88B -50.9% +12.5% 19.0 1.9%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      319
      % held
      109.2%
      Net QoQ
      +2.0M sh
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      286
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      9.9M
      Days to cover
      4.2d
      Change
      +498.9K sh
      View
      Short Volume
      Short vol %
      61%
      As of
      Aug 28, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      7.8K
      Value
      $77.9K
      As of
      Jul 16, 2026
      View
      Off-Exchange
      Off-exchange %
      34.2%
      Week of
      Jul 20, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net buying
      Net (90d)
      +$4.4K
      Buyers / Sellers
      1 / 0
      Buyers Sellers
      View
      Congressional Trades Sell
      Member
      Greg Gianforte
      Amount
      $1.0K–$15.0K
      Traded
      Oct 13, 2020
      View
      Financials
      Financials
      Revenue (FY)
      $870.4M
      Net income (FY)
      $-7.9M
      EPS diluted
      $-0.04
      View
      Buybacks
      Authorized
      shares 6.0M
      Remaining
      shares 5.9M
      Spent Remaining
      View
      Filings
      SEC Filings
      Latest
      DEF 14A
      Filed
      Aug 21, 2026
      This year
      10
      View
      Proposed Sales
      Value
      $266.6K
      Shares
      30.3K
      Filed
      Jun 3, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Jul 30, 2026
      View
      Investor Relations
      Latest news
      Neogen Reports Fourth Quarter and…
      Published
      Jul 30, 2026
      View

      Performance

      Raw-price comparisons begin at the captured split on Jun 7, 2021; windows that need an earlier baseline remain unavailable.

      5D 20D 120D MTD YTD
      NEOG -2.4% -3.2% +20.2% -3.2% +66.8%
      SPY +0.5% +3.0% +13.4% +3.0% +12.8%
      vs SPY -2.9% -6.2% +6.8% -6.2% +54.0%

      Capital returns

      Buyback program · as of May 31, 2022
      Authorized
      shares 6.00M
      Spent (derived)
      shares 100,000
      Remaining
      shares 5.90M
      Spent Remaining

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 711377 CUSIP 640491106 13F (30d) 248 filings 248 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)